Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1771 studies found for:    "Multiple myeloma"
Show Display Options
Rank Status Study
1 Completed Vaccine Therapy in Treating Patients With Multiple Myeloma
Conditions: Stage II Multiple Myeloma;   Stage III Multiple Myeloma;   Refractory Plasma Cell Neoplasm
Interventions: Drug: autologous tumor cell vaccine;   Drug: keyhole limpet hemocyanin;   Drug: melphalan;   Drug: sargramostim
2 Completed Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma
Conditions: Relapsed and Bortezomib Refractory Multiple Myeloma;   Refractory Multiple Myeloma;   Relapsed Multiple Myeloma
Interventions: Drug: panobinostat;   Drug: bortezomib;   Drug: dexamethasone
3 Recruiting Ohio State University Multiple Myeloma and Amyloidosis Data Registry and Sample Resource
Conditions: Plasma Cell Dyscrasias;   Monoclonal Gammopathy of Undetermined Significance;   AL Amyloidosis;   Multiple Myeloma
Intervention: Procedure: tissue banking
4 Active, not recruiting A Phase II Trial of Anti-KIR in Smoldering Multiple Myeloma
Conditions: Multiple Myeloma;   Myeloma;   Smoldering Multiple Myeloma
Intervention: Drug: (Anti-KIR)
5 Active, not recruiting Bortezomib in Combination With CC-5013 in Patients With Relapsed/Refractory Multiple Myeloma
Conditions: Refractory Multiple Myeloma;   Relapsed Multiple Myeloma;   Multiple Myeloma
Interventions: Drug: Bortezomib;   Drug: CC-5013
6 Recruiting A Phase 1 Study Evaluating CB-5083 in Patients With Relapsed/Refractory Multiple Myeloma
Conditions: Relapsed Multiple Myeloma;   Refractory Multiple Myeloma;   Multiple Myeloma
Interventions: Drug: CB-5083;   Drug: Dexamethasone
7 Active, not recruiting Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma
Conditions: Multiple Myeloma;   Plasma Cell Neoplasm
Interventions: Biological: filgrastim;   Biological: CD34+ cells;   Drug: cyclophosphamide;   Drug: fludarabine phosphate;   Drug: melphalan;   Drug: methotrexate;   Drug: tacrolimus
8 Active, not recruiting Vorinostat and Lenalidomide After Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma
Conditions: Multiple Myeloma;   Plasma Cell Neoplasm
Interventions: Drug: lenalidomide;   Drug: vorinostat
9 Recruiting Lenalidomide and Low-Dose Dexamethasone in Patients With Previously Treated Multiple Myeloma and Kidney Dysfunction
Conditions: Multiple Myeloma;   Plasma Cell Neoplasm
Interventions: Drug: Group A=30-60 CrCl (mL/min);   Drug: Group B=CrCL<30 mL/min not on dialysis;   Drug: Group C=CrCL<30 mL/min and on dialysis
10 Active, not recruiting Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
Conditions: Multiple Myeloma;   Plasma Cell Neoplasm
Interventions: Drug: etoposide phosphate;   Drug: melphalan;   Drug: topotecan;   Procedure: Autologous Stem Cell Rescue
11 Completed
Has Results
S0232 Dexamethasone With or Without Lenalidomide in Treating Patients With Previously Untreated Stage I, Stage II, or Stage III Multiple Myeloma
Conditions: Multiple Myeloma;   Plasma Cell Neoplasm
Interventions: Drug: dexamethasone;   Drug: lenalidomide;   Other: placebo
12 Recruiting MLN9708 (Ixazomib) in Combination With Panobinostat and Dexamethasone in Multiple Myeloma
Conditions: Multiple Myeloma;   Kahler Disease;   Plasma-Cell Myeloma;   Myelomatosis
Interventions: Drug: Panobinostat;   Drug: Dexamethasone;   Drug: MLN9708
13 Completed Ice Chips or Saline Mouth Rinse in Reducing or Preventing Mucositis in Patients Receiving Melphalan and Autologous Stem Cell Transplant for Multiple Myeloma
Conditions: Multiple Myeloma;   Plasma Cell Neoplasm
Interventions: Drug: chemoprotection;   Procedure: complementary or alternative medicine procedure;   Procedure: management of therapy complications
14 Completed A Study Evaluating the Effects of Siltuximab on the Heart in Patients With Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, or Indolent Multiple Myeloma
Conditions: Monoclonal Gammopathy of Undetermined Significance;   Multiple Myeloma;   Plasma Cell Neoplasm
Intervention: Biological: Siltuximab
15 Withdrawn Bortezomib Before Donor Stem Cell Transplant in Treating Patients With Multiple Myeloma
Conditions: Multiple Myeloma;   Refractory Multiple Myeloma
Interventions: Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation;   Procedure: allogeneic bone marrow transplantation;   Drug: bortezomib;   Drug: melphalan;   Drug: anti-thymocyte globulin;   Drug: sirolimus;   Drug: tacrolimus;   Radiation: total-body irradiation
16 Completed Vincristine, DOXIL (Doxorubicin HCl Liposome Injection) and Dexamethasone vs. Vincristine, Doxorubicin, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
Conditions: Multiple Myeloma;   Myeloma;   M-Protein;   Myeloma Proteins
Intervention: Drug: Vincristine, DOXIL (doxorubicin HCl liposomal injection), and Dexamethasone (VDD) vs. Vincristine, Doxorubicin and Dexamethasone (VAD)
17 Recruiting Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Conditions: Cancer;   Hematologic Malignancies;   Multiple Myeloma;   Oncology;   Bone Metastases;   Multiple Myeloma Bone Lesions
Interventions: Drug: Denosumab;   Drug: Zoledronic acid
18 Completed Phase I/II Study of hLL1 in Multiple Myeloma
Conditions: Multiple Myeloma;   Myeloma, Plasma-Cell;   PLASMACYTOMA
Intervention: Biological: milatuzumab
19 Recruiting Combination Study of Pomalidomide, Marizomib, and Dexamethasone in Relapsed or Refractory Multiple Myeloma
Conditions: Multiple Myeloma in Relapse;   Refractory Multiple Myeloma
Interventions: Drug: pomalidomide;   Drug: marizomib;   Drug: low-dose dexamethasone
20 Withdrawn Imaging Studies and the Development of Multiple Myeloma
Conditions: Multiple Myeloma;   Smoldering Multiple Myeloma;   Monoclonal Gammopathy of Undetermined Significance
Intervention: Drug: Fluciclatide

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years